GSK plc stock (GB0009252882): Pharma giant posts latest earnings amid vaccine and respiratory focus

GSK plc has reported its latest quarterly results, underscoring its position as a major global pharmaceutical and vaccine company as it continues to trade on both the London Stock Exchange and the New York Stock Exchange. The earnings release, published on April 29, 2026, detailed revenue trends across its core therapeutic areas, including vaccines, respiratory, and antiviral products, according to MarketBeat as of 05/08/2026.

As of May 8, 2026, GSK shares trade around 1,857.50 pence on the London Stock Exchange, with a trailing price?to?earnings ratio of about 13.2 and a market capitalization near £74 billion, according to AJ Bell as of 05/08/2026. The company also trades on the NYSE under the ticker GSK, giving U.S. investors direct access to one of the world’s largest drug manufacturers by sales, according to Simply Wall St as of 05/08/2026.

As of: 08.05.2026

By the editorial team – specialized in equity coverage.

GSK plc: core business model

GSK plc operates as a global healthcare company focused on the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company’s business model centers on large?scale R&D programs, global manufacturing networks, and commercial operations across multiple therapeutic areas, including respiratory, antiviral, and vaccine?related diseases, according to MedPath as of 05/08/2026.

Through its vaccine portfolio, GSK targets infectious diseases such as influenza, shingles, and certain respiratory viruses, while its respiratory franchise includes treatments for chronic obstructive pulmonary disease and asthma. The company also maintains a presence in antiviral therapies and specialty medicines, which together contribute a significant share of its global revenue, according to MarketBeat as of 05/08/2026.

Main revenue and product drivers for GSK plc

Recent earnings disclosures indicate that vaccines and respiratory medicines remain key revenue drivers for GSK. The company’s vaccine business benefits from broad public?health programs and seasonal demand for flu shots, while its respiratory portfolio leverages established brands and combination therapies used in chronic lung conditions, according to AJ Bell as of 05/08/2026.

Antiviral products and specialty medicines add further diversification, helping GSK manage exposure to patent expirations and generic competition in older drug lines. The company’s global footprint, with strong positions in the United States and Europe, supports recurring revenue streams from both public?sector contracts and private?sector payers, according to Simply Wall St as of 05/08/2026.

Conclusion

GSK plc remains a major player in the global pharmaceutical and vaccine sector, with diversified revenue streams from vaccines, respiratory medicines, antivirals, and specialty products. Its dual listing on the London Stock Exchange and the NYSE provides U.S. investors with exposure to a large?cap healthcare name that participates in both public?health programs and private?sector markets, according to MarketBeat as of 05/08/2026.

The company’s latest earnings highlight ongoing demand for its core products, even as it faces typical industry challenges such as patent cycles, regulatory scrutiny, and pricing pressures. For investors, GSK offers a combination of scale, international reach, and a relatively stable dividend profile, though its performance will continue to depend on pipeline execution and competitive dynamics in key therapeutic areas, according to AJ Bell as of 05/08/2026.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.